In the second segment of this roundtable series, the panel discusses the importance of safe sampling in biomarker testing.
Expert Interviews
Watch video interviews with thoracic oncology experts to learn about the latest developments in lung cancer treatment and research.
In the first segment of this roundtable series, the panel discusses the initial steps in NSCLC diagnosis and treatment.
In the seventh part of this roundtable series, the panel discusses surgical preparations and considerations.
In the sixth segment of this roundtable series, the discusses how multidisciplinary teams monitor and manage AEs.
In the fifth segment of the roundtable series, experts discuss advances in adjuvant, neoadjuvant and perioperative treatment.
In the fourth segment of this roundtable discussion, the panel shares navigation strategies for patients with NSCLC.
In the third part of this roundtable discussion, experts share insights on the decision-making process surrounding treatment
Dr. Osarogiagbon discussed the impact of the lung cancer screening program on diagnosis rates across the Mississippi Delta.
In the second segment of this roundtable discussion, experts discuss considerations surrounding biospies and biomarkers.
Dr. Jänne reflects on the importance of World Lung Cancer Day, which is marked on August 1 annually.
In the first segment of this multidisciplinary roundtable, experts discuss progress and challenges in lung cancer screening.
In the final segment of the roundtable discussion, the panel reflects on pressing unanswered questions in lung cancer.
In the fourth segment of this roundtable discussion, the panel weighs in on the most pressing unmet needs in NSCLC.
In the third segment of this roundtable discussion, the panel discusses considerations for community oncologists.
In the second segment of this roundtable discussion, the panel discusses the molecular testing landscape in NSCLC.
FLAURA2 Principal Investigator, Pasi A. Jänne, MD, PhD, discusses the final overall survival analysis from the phase 3 ...
In the first segment of this roundtable discussion, the panel explores the rising incidence of young-onset lung cancer.
In the second segment of this interview, Feldman discussed the importance of patient advocacy in clinical trial research.
Jorge Nieva, MD, explains new findings showing how steroids impact survival in patients undergoing ICI therapy.
Dr. Liu discusses the implications of the accelerated approval and what the future may hold.
Thorsten Füreder, MD, shares insights from the NSCLC cohort of the phase 2 trial.
Feldman presented on phase 2 patient-reported quality-of-life outcomes from the COCOON trial at the 2025 ASCO Annual Meeting.
Dr. Liu explains how these two studies are shaping standards of care and the treatment landscape in SCLC.
Dr. Culver discusses the organization's work at ASCO and the importance of having a patient advocacy presence at the meeting.
Xiuning Le, MD, PhD, discusses the phase 3 trial, which follows the SOHO-01 trial of the oral TKI.
The forum covered critical updates in the fields of NSCLC, SCLC, immunotherapy effectiveness, and recent trial updates.
The panel discussed advancements in the field, including results from a study of lurbinectedin plus atezolizumab for SCLC.
Dr. Osarogiagbon shared insights on findings from the incidental lung nodule program and lung cancer screening program.
Sanjay Juneja, MD, with experts Dr. Liu, Dr. Das, and Dr. Singhi, answered major questions about oncology referrals in NSCLC.
Sanjay Juneja, MD, with experts Dr. Liu, Dr. Das, and Dr. Singhi, answered major questions about recent NSCLC innovations.
Sanjay Juneja, MD, directed a discussion with Dr. Liu, Dr. Das, and Dr. Singhi on key updates in the field of NSCLC.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.